Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.05
-8.7%
$1.26
$0.90
▼
$2.98
$126.04M2.38971,152 shs913,303 shs
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
$0.80
-11.1%
$1.24
$0.78
▼
$2.99
$42.82M0.79255,942 shs408,204 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.30
+3.6%
$1.25
$0.64
▼
$1.80
$129.06M1.491.45 million shs1.67 million shs
Quanterix Corporation stock logo
QTRX
Quanterix
$2.03
-1.9%
$3.03
$1.76
▼
$8.77
$98.28M1.06651,880 shs2.13 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-8.70%+9.59%-14.63%-37.13%-35.19%
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
-11.11%-20.00%-37.98%-43.26%+79,999,900.00%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+3.60%+8.82%-9.44%-6.16%-23.82%
Quanterix Corporation stock logo
QTRX
Quanterix
-1.93%-29.02%-25.37%-32.11%-65.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.05
-8.7%
$1.26
$0.90
▼
$2.98
$126.04M2.38971,152 shs913,303 shs
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
$0.80
-11.1%
$1.24
$0.78
▼
$2.99
$42.82M0.79255,942 shs408,204 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.30
+3.6%
$1.25
$0.64
▼
$1.80
$129.06M1.491.45 million shs1.67 million shs
Quanterix Corporation stock logo
QTRX
Quanterix
$2.03
-1.9%
$3.03
$1.76
▼
$8.77
$98.28M1.06651,880 shs2.13 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-8.70%+9.59%-14.63%-37.13%-35.19%
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
-11.11%-20.00%-37.98%-43.26%+79,999,900.00%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+3.60%+8.82%-9.44%-6.16%-23.82%
Quanterix Corporation stock logo
QTRX
Quanterix
-1.93%-29.02%-25.37%-32.11%-65.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.40
Hold$6.00471.43% Upside
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
2.60
Moderate Buy$5.00525.00% Upside
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.00
Hold$4.50247.49% Upside
Quanterix Corporation stock logo
QTRX
Quanterix
1.67
Reduce$3.5072.41% Upside

Current Analyst Ratings Breakdown

Latest HYFT, QTRX, CDXS, and MXCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Codexis, Inc. stock logo
CDXS
Codexis
Reiterated RatingOverweight$5.00
11/12/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Set Price Target$4.00
11/10/2026
Quanterix Corporation stock logo
QTRX
Quanterix
Boost Price TargetHold$3.50 ➝ $4.00
11/4/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
11/4/2026
Quanterix Corporation stock logo
QTRX
Quanterix
Reiterated RatingSell (E+)
10/28/2026
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
UpgradeSell (E+) ➝ Sell (D-)
10/23/2026
Codexis, Inc. stock logo
CDXS
Codexis
UpgradeSell (E+) ➝ Sell (D-)
10/22/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
UpgradeSell (E+) ➝ Sell (D-)
10/13/2026
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
Reiterated RatingSell (E+)
10/13/2026
Quanterix Corporation stock logo
QTRX
Quanterix
Boost Price TargetHold$3.00 ➝ $3.50
10/9/2026
Codexis, Inc. stock logo
CDXS
Codexis
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M1.63N/AN/A$0.47 per share2.23
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
$11.24M3.39N/AN/A$0.18 per share4.44
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$33.03M4.05N/AN/A$1.46 per share0.89
Quanterix Corporation stock logo
QTRX
Quanterix
$138.90M0.69N/AN/A$4.62 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.20N/AN/AN/A-21.77%-43.24%-14.21%N/A
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
-$10.11M-$0.26N/AN/AN/A-105.11%-133.26%-77.78%N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$44.63M-$0.26N/AN/AN/A-81.40%-15.05%-12.79%N/A
Quanterix Corporation stock logo
QTRX
Quanterix
-$107.15M-$2.36N/AN/AN/A-75.05%-30.49%-22.44%N/A

Latest HYFT, QTRX, CDXS, and MXCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.0957-$0.08+$0.0157-$0.08$18.72 million$19.26 million
11/10/2026Q3 2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.0775-$0.05+$0.0275-$0.05$7.39 million$8.16 million
11/9/2026Q3 2026
Quanterix Corporation stock logo
QTRX
Quanterix
-$0.42-$0.46-$0.04-$0.46$33.85 million$34.97 million
9/14/2026Q1 2027
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
-$0.05-$0.09-$0.04-$0.09$3.25 million$2.73 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Quanterix Corporation stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
0.58
2.81
2.99
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
0.43
1.84
1.75
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
7.83
7.37
Quanterix Corporation stock logo
QTRX
Quanterix
N/A
3.09
2.22

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
6.70%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Quanterix Corporation stock logo
QTRX
Quanterix
86.48%

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
6.83%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
4.10%
Quanterix Corporation stock logo
QTRX
Quanterix
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
146109.60 million105.76 millionOptionable
MindWalk Holdings Corp. stock logo
HYFT
MindWalk
7747.58 million44.33 millionOptionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
91103.25 million99.02 millionOptionable
Quanterix Corporation stock logo
QTRX
Quanterix
45047.48 million46.77 millionOptionable

Recent News About These Companies

Quanterix stock gets interim CEO as Cunningham steps down
Quanterix Announces Leadership Transition Plan
Quanterix (QTRX) & Its Competitors Head-To-Head Review
Quanterix Corp (QTRX) Q3 2026 Earnings Call Transcript
What Quanterix (QTRX) Said on Its Q3 Earnings Call
Quanterix stock: Q3 2026 results set for November 9

New MarketBeat Followers Over Time

Media Sentiment Over Time

Codexis stock logo

Codexis NASDAQ:CDXS

$1.05 -0.10 (-8.70%)
As of 11/19/2026 04:00 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

MindWalk stock logo

MindWalk NASDAQ:HYFT

$0.80 -0.10 (-11.11%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$0.80 +0.00 (+0.38%)
As of 11/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$1.30 +0.05 (+3.60%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$1.29 0.00 (-0.39%)
As of 11/19/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Quanterix stock logo

Quanterix NASDAQ:QTRX

$2.03 -0.04 (-1.93%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$2.06 +0.03 (+1.23%)
As of 11/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.